Table 2.
Significant upregulated genes in resistant cell lines
| HCT116 CM-R vs HCT116 | LOVO CM-R vs LOVO | ||||
|---|---|---|---|---|---|
| Gene Name | Gene Symbol | Fold change | Gene Name | Gene Symbol | Fold change |
| Neurofibromin 1 | NF1 | 7,860,121 | Insulin-like growth factor binding protein 7 | IGFBP7 | 786,601 |
| Erb-b2 receptor tyrosine kinase 3 | ERBB3 | 6,631,199 | Insulin receptor substrate 2 | IRS2 | 7,395,454 |
| Epidermal growth factor receptor | EGFR | 5,149,977 | Amphiregulin | AREG | 4,963,224 |
| E-cadherin | CDH1 | 3,811,482 | Epidermal growth factor receptor | EGFR | 455,673 |
| Erbb2 interacting protein | ERBB2IP | 3,587,709 | Epiregulin | EREG | 4,104,191 |
| Insulin induced gene 2 | INSIG2 | 3,514,022 | Insulin induced gene 1 | INSIG1 | 3,779,914 |
| Insulin induced gene 1 | INSIG1 | 2,569,083 | Insulin induced gene 2 | INSIG2 | 3,444,767 |
| Erb-b2 receptor tyrosine kinase 2 | ERBB2 | 2,387,238 | Vimentin | VIM | 290,101 |
| Mitogen-activated protein kinase kinase kinase 10 | MAP3K10 | 2,319,185 | E-cadherin | CDH1 | 2,866,793 |
| V-akt murine thymoma viral oncogene homolog 2 | AKT2 | 2,270,916 | V-akt murine thymoma viral oncogene homolog 3 | AKT3 | 2,849,459 |
| Transforming growth factor alpha | TGFA | 2,015,933 | Transforming growth factor alpha | TGFA | 2,341,766 |
| Insulin receptor substrate 2 | IRS2 | 2,009,206 | ERBB receptor feedback inhibitor 1 | ERRFI1 | 2,141,185 |
Microarray analysis on HCT116 and LOVO resistant vs parental cell lines show recurrent upregulations of genes involved in HER, Insulin and AKT signaling